
Please try another search
By Sam Boughedda
DexCom Inc (NASDAQ:DXCM) shares jumped more than 6% Thursday after it was revealed that Medicare will cover continuous glucose monitors (CGMs) for a wider group of patients starting in April.
Citi analysts explained in a note that the updated policy from the Centers for Medicare and Medicaid Services reveals that effective April 16, to obtain CGM coverage, "Medicare beneficiaries must only be 'insulin-treated' versus 'insulin-treated with at least one daily administration of insulin,' therefore, expanding coverage to any beneficiary taking any form of insulin."
The analysts stated that Abbott has sized the Medicare basal population at 1.5 million individuals and 4M in total, including commercial, while DexCom has sized the total basal market at 3M.
"With the finalized LCD, we believe these numbers in the U.S. could be larger, a win for both ABT and DXCM. We reiterate our Buy ratings on ABT and DXCM," wrote the analysts.
Meanwhile, Stifel analysts said that basal (background insulin) coverage is "an important positive catalyst for DXCM/ABT, and could serve as a market growth accelerant."
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.